Diphenhydramine (Benadryl) - Uses, Dose, Side effects, MOA, Brands

Diphenhydramine (Benadryl) is a first-generation antihistamine. It is primarily used to treat symptoms of allergies such as itching, sneezing, urticaria, and redness.

Diphenhydramine Uses:

  • To reduce allergic reactions caused by histamine release, such as allergic dermatoses and nasal allergies
  • Treatment of anaphylaxis as an adjunct to epinephrine;
  • Insomnia
  • Prevention or treatment of motion sickness.
  • As an antitussive
  • It is also used, either alone or in combination with centrally acting anticholinergic medications, to treat Parkinsonian syndrome and drug-induced extrapyramidal symptoms, such as dystonic responses.

  • Guideline recommendations:

    • Anaphylaxis:
      • Antihistamines are only used as an additional, second-line therapy for anaphylaxis following epinephrine injection.
    • Insomnia:
      • The American Academy of Sleep Medicine does not recommend its use for insomnia.
      • According to recommendations, diphenhydramine should not be used to induce or maintain sleep in people who have chronic insomnia.
      • There is no strong evidence for clinically significant improvement.

Diphenhydramine (Benadryl) Dose in Adults

Diphenhydramine (Benadryl) Dose in the treatment of Allergic reactions:

  • Oral: maximum of 25–50 mg per 4–8 hours: 300 mg per day IM
  • IV: 10–50 mg per dosage
  • a single dose of up to 100 mg may be administered if necessary
  • not more than 400 mg each day

Diphenhydramine (Benadryl) Dose in the treatment of severe anaphylaxis as an adjunct to epinephrine; second-line agent) (off-label dose):

  • IV: over 10 to 15 minutes, 25 to 50 mg.

Diphenhydramine (Benadryl) Dose in the treatment of Antitussive:

  • Oral: 150 mg per day at a maximum of 25 mg every 4 hours.

Diphenhydramine (Benadryl) Dose in the treatment of Occasional Insomnia:

  • Oral: 50 mg before bed; note: Adults should not take this medication to cure insomnia.

Diphenhydramine (Benadryl) Dose in the treatment of Motion sickness:

Note: Give the medication prophylactically 30 minutes before the move.

  • Oral (treatment or prophylaxis): 25 to 50 mg each six to eight hours
  • 10 to 50 mg/dose (treatment) for IM and IV
  • maximum: 400 mg/day

Diphenhydramine (Benadryl) Dose in the treatment of Parkinsonism:

  • Oral: 25 - 50 mg 3 or 4 times daily
  • IM, IV: 10 - 50 mg/dose;
  • maximum: 400 mg/day

Diphenhydramine (Benadryl) Dose in the treatment of Rhinitis and sneezing due to common cold:

  • Oral: 25 - 50 mg every 4 to 6 hours;
  • maximum: 300 mg/day

Diphenhydramine (Benadryl) Dose in Children

Note:

  • There are different concentration of oral solutions: for example 12.5 mg/5 mL and 50 mg/30 mL.
  • This may create confusion between the different concentrations, precaution advised avoiding such mistakes in dose calculation and administration.
  • The dosage must be stated explicitly as "mg"; the 50 mg/30 mL oral solution is occasionally used to treat insomnia.

Diphenhydramine (Benadryl) Dose in the treatment of Allergies and Hay Fever:

  • Infants, Children, and Adolescents: Oral:

    • Weight-directed dosing:
      • 5 mg/kg/day in 3-4 divided doses;
      • maximum daily dose: 300 mg per day;
    • Age-related maximum daily doses may also be considered:
      • <6 years: 37.5 mg per day
      • 6-11 years: 150 mg per day
      • ≥12 years: 300 mg per day

  • Fixed dosing:

    • Children 2 to <6 years: Limited data available:
      • 6.25 mg every 4-6 hours;
      • maximum dose: 37.5 mg per day
    • Children 6 to <12 years:
      • 5-25 mg every 4-6 hours;
      • maximum dose: 150 mg per day
    • Children ≥12 years and Adolescents:
      • 25-50 mg every 4-6 hours;
      • maximum dose: 300 mg per day

Diphenhydramine (Benadryl) Dose in the treatment of severe allergic reaction/ anaphylaxis (as an adjunct to epinephrine):

  • Infants, Children, and Adolescents:

    • Manufacturer's labeling: IV, IM, Oral:
      • 1.25 mg/kg/dose given every 6 hours;
      • The maximum dose is 300 mg per day
    • Alternate dosing: IV, IM, Oral:
      • 1-2 mg/kg/dose;
      • The maximum single dose is 50 mg/dose

Diphenhydramine (Benadryl) Dose in the treatment of Rhinitis and sneezing due to common cold: Oral:

  • Children 6 to <12 years:

    • 25 mg every 4-6 hours;
    • The maximum dose is 150 mg per day.

  • Children ≥12 years and Adolescents:

    • 25-50 mg every 4-6 hours;
    • The maximum dose is 300 mg per day.

Diphenhydramine (Benadryl) Dose in the treatment of Dystonic reactions:

  • Infants, Children, and Adolescents:

    • IV, IM: 1-2 mg/kg/dose;
    • The maximum single dose is 50 mg

Diphenhydramine (Benadryl) Dose in the treatment of Motion sickness:

  • Infants, Children, and Adolescents:

    • Prophylaxis: Oral:

      • Manufacturer's labeling:
        • 30 minutes before travel, administer the first dose
      • Weight-directed dosing:
        • 5 mg/kg/day in 3-4 divided doses;
        • The maximum dose is 300 mg per day
      • Fixed dosing:
        • 5-25 mg 3-4 times daily
      • Alternate dosing: Children 2-12 years: Limited data available:
        • 0.5-1 mg/kg/dose every 6 hours;
        • The maximum single dose is 25 mg.
        • Administered the first dose 1 hour before travel.

    • Treatment:

      • IV, IM:
        • 1.25 mg/kg/dose every 6 hours;
        • maximum dose: 300 mg per day
      • Oral:
        • Weight-directed dosing:
          • 5 mg/kg/day divided into 3-4 doses;
          • maximum dose: 300 mg per day
        • Fixed dosing:
          • 5-25 mg 3-4 times a day

Diphenhydramine (Benadryl) Dose in the treatment of occasional insomnia: Oral:

  • Children 2-12 years, weighing 10-50 kg: Limited data available:

    • 1 mg/kg 30 minutes before bedtime;
    • The maximum single dose is 50 mg

  • Children ≥12 years and Adolescents:

    • 50 mg 30 minutes before bedtime

Diphenhydramine (Benadryl) Dose in the treatment of Pruritus (opioid-induced): Limited data available:

  • Infants, Children, and Adolescents:

    • IM, IV, Oral:
      • 0.5-1 mg/kg/dose every 6 hours;
      • The maximum dose: 100 mg per day

Diphenhydramine (Benadryl) Dose in the treatment of Urticaria:

  • Infants, Children, and Adolescents: Oral:

    • Weight-directed dosing:
      • 5 mg/kg/day in 3-4 divided doses;
      • The maximum dose: 300 mg per day
    • Fixed dosing:
      • 5-25 mg 3-4 times a day

Pregnancy Risk Factor B

  • If given right before parturition, diphenhydramine can cross the placenta. This could cause respiratory depression in newborns.
  • Diphenhydramine can be used to treat allergic conditions when an antihistamine of first-generation is prescribed for a pregnant woman
  • Diphenhydramine may also be used in conjunction with preferred agents if there is no relief from nausea or vomiting.
  • Antihistamines should not be used if pruritus is caused by intrahepatic cholesterol during pregnancy

Use of diphenhydramine during breastfeeding

  • Breast milk contains diphenhydramine. It is not recommended for breastfeeding.
  • The possibility of drowsiness may be caused by infant exposure.
  • The first-generation antihistamine administered via breast milk can cause irritability or drowsiness.
  • This should be checked for. When necessary, 2nd-generation antihistamines should be used in lactating mothers
  • Infants who are not yet born are more likely to be sensitive to anti-histamines
  • If given prior to the establishment of lactation, it may reduce the production of maternal Prolactin.

Dose in Kidney Disease:

No dose adjustments listed in the manufacturer’s labeling.

Dose in Liver disease:

No dose adjustments listed in the manufacturer’s labeling.

Side effects of Diphenhydramine (Benadryl):

  • Cardiovascular:

    • Chest Tightness
    • Extrasystoles
    • Hypotension
    • Palpitations
    • Tachycardia

  • Central Nervous System:

    • Ataxia
    • Chills
    • Confusion
    • Dizziness
    • Drowsiness
    • Euphoria
    • Excitement
    • Fatigue
    • Headache
    • Irritability
    • Nervousness
    • Neuritis
    • Paradoxical Excitation
    • Paresthesia
    • Restlessness
    • Sedation
    • Seizure
    • Vertigo

  • Dermatologic:

    • Diaphoresis
    • Skin Photosensitivity
    • Skin Rash
    • Urticaria

  • Gastrointestinal:

    • Anorexia
    • Constipation
    • Diarrhea
    • Dry Mucous Membranes
    • Epigastric Distress
    • Nausea
    • Vomiting
    • Xerostomia

  • Genitourinary:

    • Difficulty In Micturition
    • Urinary Frequency
    • Urinary Retention

  • Hematologic & Oncologic:

    • Agranulocytosis
    • Hemolytic Anemia
    • Thrombocytopenia

  • Hypersensitivity:

    • Anaphylactic Shock

  • Neuromuscular & Skeletal:

    • Tremor

  • Ophthalmic:

    • Blurred Vision
    • Diplopia

  • Respiratory:

    • Nasal Congestion
    • Pharyngeal Edema
    • Thickening Of Bronchial Secretions
    • Wheezing

Contraindications to Diphenhydramine (Benadryl):

  • Hypersensitivity to any component diphenhydramine
  • Premature infants or neonates
  • Breastfeeding
  • Local anesthesia using parenteral injections

Labeling of over-the-counter (OTC), products:

  • If used as self-medication, it is not recommended for children under 6 years of age.
  • Other diphenhydramine-containing products including topical products should also be given with caution below 6 years as self-medication

Warnings and precautions

  • CNS depression:

    • CNS depression may be caused by diphenhydramine, which can impair mental or physical abilities. 
    • Driving or performing other tasks that call on mental clarity can be risky. Patients should be aware of these effects.

  • Asthma

    • Asthmatic patients should be cautious

  • Cardiovascular disease

    • Patients with cardiovascular diseases such as hypertension or ischemic heart disease (IHD), should be cautious.

  • Glaucoma/increased intraocular pressure

    • Patients with angle-closure or other conditions that increase intraocular pressure should be cautious

  • Prostatic hyperplasia/urinary block:

    • Patients with genitourinary and prostatic obstruction (BPH), bladder neck obstruction, or genitourinary hyperplasia (GPH) should be cautious

  • Occlusion of the pyloroduodenum:

    • Caution is advised for stenotic peptic and pyloroduodenal blockages

  • Thyroid dysfunction:

    • Thyroid dysfunction: Be cautious

Diphenhydramine (systemic): Drug Interaction

Risk Factor C (Monitor therapy).
Acetylcholinesterase inhibitors Anticholinergic Agents may have a decreased therapeutic effect. Anticholinergic Agents can decrease the therapeutic effects of Acetylcholinesterase inhibitors.
Alcohol (Ethyl) Alcohol's CNS depressing effects can be amplified by CNS depressants (Ethyl).
Alizapride CNS Depressants may intensify the effects of CNS Depressants.
Amantadine Anticholinergic Agents may have an enhanced anticholinergic effect.
Amezinium Amezinium may have a stronger stimulatory effect if it is combined with antihistamines.
Amphetamines May lessen antihistamines' sedative effects.
Anticholinergic Agents Other anticholinergic agents could be harmful or poisonous.
ARIPiprazole CYP2D6 inhibitors (Weak) may raise ARIPiprazole's serum levels. It's crucial to keep an eye out for any heightened pharmacologic effects of aripiprazole. Depending on the indication and concurrent medication, aripiprazole dosage modifications may be required.
Betahistine Consult the interaction monograph in its entirety for more details. Antihistamines may lessen the therapeutic effects of betahistine.
Blonanserin Blonanserin's CNS depressing effects can be amplified by other CNS depressants.
Botulinum Toxin-Containing Products Agents that are anticholinergic may have a stronger anticholinergic impact.
Brexanolone CNS Depressants can increase the CNS depressant effects of Brexanolone.
Brimonidine (Topical) CNS Depressants may increase the CNS depressant effects.
Bromopride CNS Depressants may increase the CNS depressant effects.
Cannabidiol CNS Depressants may increase the CNS depressant effects.
Cannabis CNS Depressants may increase the CNS depressant effects.
Chloral Betaine Anticholinergic Agents may have an adverse/toxic effect.
Chlorphenesin Carbamate CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
CNS Depressants Can increase the toxic/adverse effects of CNS Depressants.
Dimethindene (Topical). CNS Depressants may increase the CNS depressant effects.
Doxylamine If taken alongside other CNS Depressants, CNS Depressants may have a stronger CNS depressing impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants.
Dronabinol CNS Depressants may intensify the effects of CNS Depressants.
Esketamine CNS Depressants may intensify the effects of CNS Depressants.
Gastrointestinal Agents (Prokinetic) The therapeutic effects of gastrointestinal agents can be lessened by anticholinergic agents (Prokinetic).
Glucagon Anticholinergic medications may make glucagon more toxic or harmful.
There may be a greater chance of unpleasant gastrointestinal effects in particular.
HydrOXYzine CNS Depressants may intensify the effects of CNS Depressants.
Itopride Itopride's therapeutic effects may be diminished by anticholinergic agents.
Kava Kava CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
Lofexidine CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph.
Magnesium Sulfate CNS Depressants may intensify the effects of CNS Depressants.
MetyroSINE MetyroSINE may have a sedative effect that can be enhanced by CNS depressants.
Mianserin Anticholinergic Agents may have an enhanced anticholinergic effect.
Minocycline CNS Depressants may intensify the effects of CNS Depressants.
Mirabegron Anticholinergic medications may worsen Mirabegron's harmful or severe effects.
Mirtazapine The CNS depressing effects of mirtazapine can be intensified by CNS depressants.
Nabilone CNS Depressants can increase the CNS depressant effects of Mirtazapine.
Nitroglycerin The absorption of Nitroglycerin may be decreased by anticholinergic agents.
Perhexiline Perhexiline serum concentration may be increased by CYP2D6 inhibitors (Weak).
Piribedil Piribedil's CNS depressing effects could be amplified by other CNS depressants.
Pitolisant Pitolisant's therapeutic effects can be lessened by antihistamines.
Pramipexole Pramipexole may have a greater sedative effect if it is combined with CNS depressants.
Ramosetron Ramosetron's constipating effects may be enhanced by anticholinergic agents.
ROPINIRole CNS Depressants can increase the sedative effects of ROPINIRole.
Rotigotine CNS Depressants can increase the sedative effects of Rotigotine.
Rufinamide CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased.
Selective Serotonin Reuptake inhibitors CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased.
Tetrahydrocannabinol CNS Depressants may increase the CNS depressant effects.
Tetrahydrocannabinol, and Cannabidiol CNS Depressants may intensify the effects of CNS Depressants.
Thiazide and Thiazide - Like Diuretics Anticholinergic Agents can increase serum Thiazide or Thiazide-Like Diuretics.
Topiramate Topiramate's toxic/adverse effects may be exacerbated by anticholinergic agents.
Trimeprazine CNS Depressants may intensify the effects of CNS Depressants.

Risk Factor D (Consider therapy modifications)
Benzylpenicilloyl polylysine Benzylpenicilloyl Polylysine's diagnostic potency may be diminished by antihistamines. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. A histamine skin test can be used to check for lingering antihistaminic effects.
Buprenorphine CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults, when taken with other CNS depression drugs.
Chlormethiazole CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used.
Droperidol CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph.
Flunitrazepam CNS Depressants can increase the CNS depressant effects of Flunitrazepam.
Hyaluronidase Hyaluronidase's therapeutic effects may be diminished by antihistamines. Patients who are taking antihistamines, especially at higher doses, may not have the desired clinical response to standard doses hyaluronidase. Higher doses of hyaluronidase might be necessary.
HYDROcodone CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Methotrimeprazine Compared to CNS Depressants, methotrimeprazine may have a stronger CNS depressant action.  The CNS depressant effects of CNS depressants can be intensified by methotrimeprazin. Management: Start concurrent methotrimeprazine therapy and reduce the adult CNS depressant dose by 50%. Only once methotrimeprazine's clinical efficacy has been established should CNS depressant dose modifications be considered.
Opioid Agonists Opioid agonists' CNS depressing effects can be amplified by CNS depressants. Management: When using opioid agonists and other CNS depressants simultaneously, try to avoid doing so. It is not advised to combine these medications unless there are better alternatives. When taking multiple drugs, keep dosage and duration to a minimum.
OxyCODONE CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Perampanel CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination.
Pramlintide Anticholinergic Agents may have an enhanced anticholinergic effect. These effects are only for the GI tract.
Secretin Secretin's therapeutic effects may be diminished by anticholinergic agents. Concomitant use: Secretin and anticholinergic agents should be avoided. Stop using anticholinergic drugs for at least five half-lives before administering secretin.
Sodium Oxybate CNS Depressants may have a greater depressant effect if taken in combination. Management: Look for alternatives to the combination use. If you must combine use, reduce the doses of any one or more drugs. It is not recommended to combine sodium oxybate and alcohol, or any sedative hypnotics.
Suvorexant CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia.
Tapentadol CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Zolpidem Zolpidem's CNS depressing effects can be intensified by CNS depressants. Treatment: Lower the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg for males who also use CNS depressants. No dose change is suggested for females.
Avoid taking CNS depressants and alcohol at night.

Risk Factor X (Avoid Combination)
Aclidinium Anticholinergic Agents may have an enhanced anticholinergic effect.
Azelastine (Nasal) CNS Depressants could increase the CNS depressant effects of Azelastine.
Bromperidol CNS Depressants may increase the CNS depressant effects.
Cimetropium Cimetropium may have an anticholinergic effect that can be enhanced by the use of anticholinergic agents.
Eluxadoline Eluxadoline may cause constipation by using anticholinergic agents.
Glycopyrrolate (Oral Inhalation) Anticholinergic agents may increase the anticholinergic effects of Glycopyrrolate (Oral inhalation).
Glycopyrronium (Topical) Anticholinergic Agents may have an enhanced anticholinergic effect.
Oral Inhalation with Ipratropium Anticholinergic Agents may have an enhanced anticholinergic effect.
Levosulpiride Anticholinergic Agents can reduce the therapeutic effects of Levosulpiride.
Orphenadrine Orphenadrine may be more effective against CNS depression than other drugs.
Oxatomide Anticholinergic Agents may have an enhanced anticholinergic effect.
Oxomemazine CNS Depressants may increase the CNS depressant effects.
Paraldehyde Paraldehyde may be enhanced by CNS Depressants.
Potassium Chloride Potassium Chloride may have an ulcerogenic effect that can be exacerbated by anticholinergic agents. 
Potassium Citrate If potassium citrate is administered with anticholinergic drugs, it can increase the risk of ulcers.
Revefenacin Revefenacin may be enhanced by anticholinergic agents.
Thalidomide CNS Depressants can increase Thalidomide's CNS depressant effects.
Tiotropium Anticholinergic agents may increase the anticholinergic effects of Tiotropium.
Umeclidinium Anticholinergic Agents may have an enhanced anticholinergic effect.

Monitoring parameters:

  • Relief of symptoms
  • mental alertness

How to administer Diphenhydramine (Benadryl)?

Oral:

  • Give 30 minutes before exposure as prophylaxis for motion sickness.
  • Given 30 minutes before bedtime for occasional insomnia

IM, IV: IV or deep IM administration only. Not for the subcutaneous or intradermal route

  • IV: Inject at a rate of 25 mg or less per minute. There may be Local necrosis with subcutaneous or intradermal use.

Mechanism of action of Diphenhydramine (Benadryl):

  • There are many sites where H1 receptors can be found, including the gastrointestinal smooth muscle, blood vessels, respiratory tract, and respiratory system. 
  • Diphenhydramine counteracts the effects of histamine by competing with it for H1-receptor sites in the effector cells of these organs.
  • You can also see anticholinergic, sedative and other effects.

Duration:

  • Histamine-induced wheal suppression: ≤10 hours
  • Histamine-induced flare suppression: ≤12 hours

Protein binding:

  • 98.5%

Metabolism:

  • Mainly hepatic n-demethylation via CYP2D6; minor demethylation via CYP1A2, 2C9, and 2C19
  • smaller degrees in pulmonary and renal systems
  • There is a significant first-pass effect

Bioavailability:

  • 42% to 62%

Half-life elimination:

  • Children: 5 hours (range: 4 to 7 hours)
  • Adults: 9 hours (range: 7 to 12 hours)
  • Elderly: 13.5 hours (range: 9 to 18 hours)

Time to peak, serum:

  • About 2 hours

Excretion:

  • Through Urine as metabolites and unchanged drug.

International Brand Names of Diphenhydramine:

  • Aler-Dryl
  • Allergy Relief Childrens
  • Allergy Relief
  • Altaryl
  • Anti-Hist Allergy
  • Banophen
  • Benadryl Allergy Childrens
  • Benadryl Allergy
  • Benadryl Dye-Free Allergy
  • Complete Allergy Medication
  • Complete Allergy Relief
  • Diphen
  • Diphenhist
  • Genahist
  • Geri-Dryl
  • GoodSense Allergy Relief
  • GoodSense Sleep Aid
  • Naramin
  • Nighttime Sleep Aid
  • Nytol Maximum Strength
  • Nytol
  • Ormir
  • PediaCare Childrens Allergy
  • Pharbedryl
  • Q-Dryl
  • QlearQuil Nighttime Allergy
  • Quenalin
  • ScotTussin Allergy Relief
  • Siladryl Allergy
  • Silphen Cough
  • Simply Sleep
  • Sleep Tabs
  • Sominex Maximum Strength
  • Sominex
  • TetraFormula Nighttime Sleep
  • Total Allergy Medicine
  • Total Allergy
  • Triaminic Cough/Runny Nose
  • ZzzQuil
  • Diphenist
  • PMS-DiphenhydrAMINE
  • Aliserin
  • Allermin
  • Amydramine
  • Amydramine-II
  • Amydramkine-II
  • Azaron
  • Beanamine
  • Belarmin
  • Belarmin Expectorant
  • Bena
  • Benadrex
  • Benadryl
  • Benadryl A
  • Benadryl Allergy
  • Benadryl for the Family Original
  • Benamine
  • Bendol
  • Benocten
  • Benylan
  • Bexil
  • Butix
  • Calm U
  • Calmaben
  • Cerylana
  • Daedalon
  • Danzamin
  • Desentol
  • DiBendryl
  • Dibrondrin
  • Didra
  • Didryl
  • Difenidrin
  • Dormital
  • Dormutil
  • Dramylin
  • Exylin
  • Fenilar
  • Histergan
  • Hydramine
  • Hydrazol
  • Hyphen
  • Menna
  • Nardyl
  • Otede
  • Pediphen
  • Phenadryl
  • Phenycof
  • Psilo Balsam
  • R Calm
  • Rabaphen
  • Recodryl
  • Resmin
  • Rivedramine
  • Rosmylin Expectorant
  • Sleepeze-PM
  • Snuzaid
  • Somol
  • Soniphen
  • Sonodor
  • Stopkof P
  • Sultan
  • Unisom Sleepgels
  • Valdres
  • Vena
  • Venapas Oint
  • Venasmin
  • Vertirosan
  • Vivinox

Diphenhydramine Brand Names in Pakistan:

Diphenhydramine Syrup 5 mg/5ml in Pakistan
Hydilar-Dm Atlantic Pharmaceuticals (Pvt) Ltd.

 

Diphenhydramine Syrup 13.5 mg/5ml in Pakistan
D-Hydri Sayyed Pharmaceuticals
Recent Posts
  • Donanemab (Kisunla) FDA Approved for Alzheimer's Disease
    17-07-2024
  • How Can We Prevent the Long-Term Complications of Diabetes?
    20-06-2024
  • Monoclonal Antibody Offers Seasonal Protection From Malaria
    19-06-2024
  • IMDELLTRA (tarlatamab-dlle) FDA Prescribing Information for SCLC
    29-05-2024
Related Posts
Flunisolide for Oral Inhalation - Uses, Dose, Side effects, MOA
13-12-2021
Fluticasone Inhaler (Flovent HFA, Flixotide) - Dose, Side effects, MOA
13-12-2021
Fluticasone Nasal Spray (Avamys, Flixonase) - Uses, Dose, MOA, Brands
13-12-2021
Formoterol (Perforomist, Foradil) - Uses, Dosage, Side effects, MOA, Brands
13-12-2021